市场调查报告书

骨癌的全球市场分析:至2025年的预测

Global Osteosarcoma Market Research Report - Forecast till 2025

出版商 Market Research Future 商品编码 922982
出版日期 内容资讯 英文 103 Pages
订单完成后即时交付
价格
骨癌的全球市场分析:至2025年的预测 Global Osteosarcoma Market Research Report - Forecast till 2025
出版日期: 2019年12月01日内容资讯: 英文 103 Pages
简介

全球骨癌市场至2025年预计将以6.09%的年复合成长率成长,成长到7亿9,108万美元的规模。骨癌,是骨头出现的恶性肿瘤,主要好发于青少年和年轻人,老年人。这个市场,由于骨癌的发生率高,及肿瘤研究的支出的增加,新治疗药的需求高涨等促进成长。各地区中,南北美洲2018年获得40.02%的市场占有率,成为最大市场。

本报告提供全球骨癌市场调查,市场概要,各类型、诊断、治疗方法、终端用户、地区的市场规模的变化与预测,市场成长要素及阻碍因素分析,市场机会,竞争情形,主要企业的简介等,全面性资讯。

目录

目录

第1章 摘要整理

  • 概要
  • 市场概要
  • 主要的贡献要素

第2章 市场简介

  • 定义
  • 调查范围
  • 研究目的
  • 市场结构

第3章 调查方法

  • 调查方法
  • 一次研究
  • 二次研究
  • 市场规模估计
  • 预测模式
  • 假设的清单

第4章 市场动态

  • 概要
  • 驾驶人
    • 骨癌的高发生率
    • 肿瘤医学及研究相关支出的增加
    • 新的治疗的需求高涨
  • 阻碍因素
    • 治疗的高成本
    • 化疗的副作用
  • 市场机会
    • 开发经济的进入
  • 宏觀经济指标

第5章 市场影响要素分析

  • 波特的五力分析
  • 价值链分析
    • 研究开发、设计
    • 制造
    • 流通
    • 行销销售
    • 销售后监测
  • 流行病学资料
  • 临床试验分析
  • 开发平台分析
    • Pemetrexed
    • 吸入脂质CISPLATIN

第6章 全球骨癌市场:各类型

  • 概要
  • 髓内骨癌
  • 皮质旁骨肉瘤
  • 外骨骼性骨癌

第7章 全球骨癌市场:各诊断、治疗法

  • 概要
  • 治疗方法
    • 化疗
    • 手术
    • 放射线治疗
  • 诊断
    • 成像
    • 切片检查
    • 血液检验

第8章 全球骨癌市场:各终端用户

  • 概要
  • 医院、诊所
  • 诊断中心
  • 学术、研究机关

第9章 全球骨癌市场:各地区

  • 概要
  • 南北美洲
    • 北美
    • 中南美
  • 欧洲
    • 西欧
    • 东欧
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 其他
  • 中东、非洲
    • 中东
    • 非洲

第10章 竞争情形

  • 概要
  • 主要趋势

第11章 企业简介

  • PFIZER INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • BAXTER INTERNATIONAL
  • NOVARTIS AG
  • AUROBINDO PHARMA LIMITED
  • HIKMA PHARMACEUTICALS PLC
  • MYLAN NV
  • ADVAXIS, INC.

第12章 附录

  • 参考文献
  • 相关报告
目录

Global Osteosarcoma Market: Information by Type (Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extraskeletal Osteosarcoma), Diagnosis & Treatment (Treatment and Diagnosis), End User (Hospitals & Clinics, Diagnostic Centres and Academic & Research Organizations), by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market Analysis:

Osteosarcoma Market is expected to register a CAGR of 6.09% to reach USD 791.08 Million by the year 2025. Osteosarcoma is a common type of bone cancer which is developed in cells which are responsible for formation of bones. In very rare conditions osteosarcoma happens in soft tissue outside the bones. Usually, it mostly occurs in teenagers, young adults, and older adult population. The global osteosarcoma market is predominantly driven by a high incidence of osteosarcoma, increasing expenditure on oncology medicine and research, and growing demand for new treatments. Nevertheless, the high cost of treatment and side-effects of chemotherapy impede the growth of the market. The Global Osteosarcoma Market is taking shape due to a higher incidence of osteosarcoma. For example, the prevalence of primary bone cancer is growing across the world. Under national Institutes of Health (NIH), estimation of around 3,450 new cases of primary bone cancer was registered in 2018 in the US. A high number of incidences of osteosarcoma would support the growth of the market. As per the American Cancer Society, around 800 to 900 new cases of osteosarcoma are diagnosed in the US each year. The incidence of osteosarcoma is found to be high in adolescents and the geriatric population. Similarly, according to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in the year 2018. Additionally, the National Cancer Institute's Surveillance, Epidemiology, and End Results Program estimated the incident rate of 4.4 cases per 1 million people below the age of 24 years in the US each year. The cumulative prevalence of osteosarcoma along with the increasing geriatric population are driving the global osteosarcoma market.

Market Segmentation:

The Global Osteosarcoma Market has been segmented into type, diagnosis & treatment, end user, and region. Based on type the Global Osteosarcoma Market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extra skeletal osteosarcoma. Intramedullary osteosarcoma has been estimated to account for the largest market share of 80.3% during the forecast period. Intramedullary osteosarcoma is the most common type of osteosarcoma, which represents approximately 75% of all reported osteosarcoma cases recorded globally. Typically, intramedullary osteosarcoma occurs in children and adults. This type of osteosarcoma is bimodal and primarily peaks during adolescence, and the second peak occurs in adulthood. The distal femur and proximal tibia are two primary sites impacted by intramedullary osteosarcoma. Based on diagnosis & treatment, the global osteosarcoma market has been divided into the treatment and diagnosis. The treatment segment is further divided into chemotherapy, surgery, radiation therapy, and others. The chemotherapy segment includes cisplatin, doxorubicin, epirubicin, and others. The surgery segment contains a limb-sparing surgery and amputation. The diagnosis segment is even more segmented into imaging, biopsies, and blood tests. The imaging segment comprises computerized tomography (CT), magnetic resonance imaging (MRI), X-Ray, positron emission tomography (PET) and others. The biopsies segment includes needle biopsy and surgical biopsy. The blood tests segment includes alkaline phosphatase profiling, lactate dehydrogenase profiling, and others. Based on end-user, the global osteosarcoma market has been divided into hospitals & clinics, diagnostic centres, and academic & research organizations. Its hold biggest market share could be attributed to an increase in the number of patients who have cancer, coupled with a rise in a number of hospitals, and quality care, as well as the availability of skilled and qualified professionals.

Regional Analysis:

The Global Osteosarcoma Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas represent a market share of 40.02% in the year 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada. Europe was the second-largest global osteosarcoma market in the year 2018. The Europe region is even more segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries, has been divided into the Germany, the UK, France, Italy, Spain, and the rest of Western Europe. The Asia-Pacific region was classified as China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. It holds the third-largest position in the osteosarcoma market. The market in the Middle East & Africa is likely to show minimum growth by factors such as limited access to and higher availability of treatment facilities. However, the high prevalence of bone cancer population will support growth of the market in the region during the forecast period.

Major Players:

Academic research institutes, Pharmaceutical companies, Biotechnology companies and Market research & consulting firms are some of the projected onlookers for the Global Osteosarcoma Market. Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. are some of the major players in the Global Osteosarcoma Market.

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 OVERVIEW
  • 1.2 MARKET SYNOPSIS
  • 1.3 KEY CONTRIBUTING FACTORS

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 RESEARCH PROCESS
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION
  • 3.5 FORECAST MODEL
  • 3.6 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 HIGH INCIDENCE OF OSTEOSARCOMA
    • 4.2.2 RISING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH
    • 4.2.3 RISING DEMAND FOR NEW TREATMENTS
  • 4.3 RESTRAINTS
    • 4.3.1 HIGH COST OF TREATMENT
    • 4.3.2 SIDE-EFFECTS OF CHEMOTHERAPY
  • 4.4 OPPORTUNITIES
    • 4.4.1 ENTERING DEVELOPING ECONOMIES
  • 4.5 MACROECONOMIC INDICATORS

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES MODEL
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 VALUE CHAIN ANALYSIS
    • 5.2.1 R&D AND DESIGNING
    • 5.2.2 MANUFACTURING
    • 5.2.3 DISTRIBUTION
    • 5.2.4 MARKETING & SALES
    • 5.2.5 POST-SALES MONITORING
  • 5.3 EPIDEMIOLOGY DATA
  • 5.4 CLINICAL TRIALS ANALYSIS
  • 5.5 PIPELINE ANALYSIS
    • 5.5.1 PEMETREXED
    • 5.5.2 INHALED LIPID CISPLATIN

6 GLOBAL OSTEOSARCOMA MARKET, BY TYPE

  • 6.1 OVERVIEW
  • 6.2 INTRAMEDULLARY OSTEOSARCOMA
  • 6.3 JUXTACORTICAL OSTEOSARCOMA
  • 6.4 EXTRASKELETAL OSTEOSARCOMA

7 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT

  • 7.1 OVERVIEW
  • 7.2 TREATMENT
    • 7.2.1 CHEMOTHERAPY
    • 7.2.2 SURGERY
    • 7.2.3 RADIATION THERAPY
  • 7.3 DIAGNOSIS
    • 7.3.1 IMAGING
    • 7.3.2 BIOPSIES
    • 7.3.3 BLOOD TESTS

8 GLOBAL OSTEOSARCOMA MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 HOSPITALS & CLINICS
  • 8.3 DIAGNOSTIC CENTERS
  • 8.4 ACADEMIC & RESEARCH ORGANIZATIONS

9 GLOBAL OSTEOSARCOMA MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 AMERICAS
    • 9.2.1 NORTH AMERICA
    • 9.2.2 LATIN AMERICA
  • 9.3 EUROPE
    • 9.3.1 WESTERN EUROPE
    • 9.3.2 EASTERN EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 JAPAN
    • 9.4.2 CHINA
    • 9.4.3 INDIA
    • 9.4.4 SOUTH KOREA
    • 9.4.5 REST OF ASIA-PACIFIC
  • 9.5 MIDDLE EAST & AFRICA
    • 9.5.1 MIDDLE EAST
    • 9.5.2 AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY DEVELOPMENTS

11 COMPANY PROFILES

  • 11.1 PFIZER INC.
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS/SERVICES OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 BRISTOL-MYERS SQUIBB COMPANY
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS/SERVICES OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 EY STRATEGIES
  • 11.3 ELI LILLY AND COMPANY
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS/SERVICES OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 SWOT ANALYSIS
    • 11.3.6 KEY STRATEGIES
  • 11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS/SERVICES OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGIES
  • 11.5 BAXTER INTERNATIONAL
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS/SERVICES OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 SWOT ANALYSIS
    • 11.5.6 KEY STRATEGIES
  • 11.6 NOVARTIS AG
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS/SERVICES OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 SWOT ANALYSIS
    • 11.6.6 KEY STRATEGIES
  • 11.7 AUROBINDO PHARMA LIMITED
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS/SERVICES OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 SWOT ANALYSIS
    • 11.7.6 KEY STRATEGIES
  • 11.8 HIKMA PHARMACEUTICALS PLC
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS/SERVICES OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 SWOT ANALYSIS
    • 11.8.6 KEY STRATEGIES
  • 11.9 MYLAN NV
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS/SERVICES OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 SWOT ANALYSIS
    • 11.9.6 KEY STRATEGIES
  • 11.10 ADVAXIS, INC.
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS/SERVICES OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 SWOT ANALYSIS
    • 11.10.6 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS

List of Tables

LIST OF TABLES

  • TABLE 1 PRIMARY INTERVIEWS
  • TABLE 2 LIST OF ASSUMPTIONS
  • TABLE 3 INCIDENCE OF OSTEOSARCOMA, BY AGE IN THE US
  • TABLE 4 CLINICAL TRIALS
  • TABLE 5 PIPELINE ANALYSIS
  • TABLE 6 GLOBAL OSTEOSARCOMA MARKET, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 7 GLOBAL INTRAMEDULLARY OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 8 GLOBAL JUXTACORTICAL OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 9 GLOBAL EXTRASKELETAL OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 10 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 11 GLOBAL TREATMENT: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 12 GLOBAL TREATMENT: MARKET ESTIMATES & FORECAST, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 13 GLOBAL CHEMOTHERAPY: MARKET ESTIMATES & FORECAST, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 14 GLOBAL SURGERY: MARKET ESTIMATES & FORECAST, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 15 GLOBAL DIAGNOSIS: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 16 GLOBAL DIAGNOSIS: MARKET ESTIMATES & FORECAST, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 17 GLOBAL IMAGING: MARKET ESTIMATES & FORECAST, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 18 GLOBAL BIOPSIES: MARKET ESTIMATES & FORECAST, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 19 GLOBAL BLOOD TESTS: MARKET ESTIMATES & FORECAST, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 20 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 21 GLOBAL HOSPITALS & CLINICS: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 22 GLOBAL DIAGNOSTIC CENTERS: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 23 GLOBAL ACADEMIC INSTITUTES & RESEARCH ORGANIZATIONS: MARKET ESTIMATES & FORECAST, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 24 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 25 AMERICAS: OSTEOSARCOMA MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 26 AMERICAS: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 27 AMERICAS: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 28 AMERICAS: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 29 AMERICAS: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 30 AMERICAS: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 31 AMERICAS: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 32 AMERICAS: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 33 AMERICAS: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 34 AMERICAS: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 35 AMERICAS: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 36 NORTH AMERICA: OSTEOSARCOMA MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 37 NORTH AMERICA: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 38 NORTH AMERICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 39 NORTH AMERICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 40 NORTH AMERICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 41 NORTH AMERICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 42 NORTH AMERICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 43 NORTH AMERICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 44 NORTH AMERICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 45 NORTH AMERICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 46 NORTH AMERICA: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 47 US: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 48 US: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 49 US: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 50 US: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 51 US: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 52 US: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 53 US: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 54 US: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 55 US: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 56 CANADA: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 57 CANADA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 58 CANADA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 59 CANADA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 60 CANADA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 61 CANADA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 62 CANADA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 63 CANADA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 64 CANADA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 65 CANADA: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 66 LATIN AMERICA: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 67 LATIN AMERICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 68 LATIN AMERICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 69 LATIN AMERICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 70 LATIN AMERICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 71 LATIN AMERICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 72 LATIN AMERICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 73 LATIN AMERICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 74 LATIN AMERICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 75 LATIN AMERICA: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 76 EUROPE: OSTEOSARCOMA MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 77 EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 78 EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 79 EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 80 EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 81 EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 82 EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 83 EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 84 EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 85 EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 86 EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 87 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 88 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 89 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 90 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 91 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 92 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 93 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 94 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 95 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 96 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 97 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 98 GERMANY: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 99 GERMANY: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 100 GERMANY: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 101 GERMANY: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 102 GERMANY: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 103 GERMANY: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 104 GERMANY: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 105 GERMANY: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 106 GERMANY: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 107 GERMANY: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 108 FRANCE: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 109 FRANCE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 110 FRANCE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 111 FRANCE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 112 FRANCE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 113 FRANCE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 114 FRANCE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 115 FRANCE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 116 FRANCE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 117 FRANCE: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 118 UK: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 119 UK: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 120 UK: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 121 UK: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 122 UK: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 123 UK: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 124 UK: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 125 UK: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 126 UK: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 127 UK: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 128 ITALY: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 129 ITALY: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 130 ITALY: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 131 ITALY: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 132 ITALY: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 133 ITALY: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 134 ITALY: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 135 ITALY: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 136 ITALY: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 137 ITALY: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 138 SPAIN: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 139 SPAIN: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 140 SPAIN: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 141 SPAIN: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 142 SPAIN: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 143 SPAIN: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 144 SPAIN: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 145 SPAIN: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 146 SPAIN: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 147 SPAIN: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 148 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 149 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 150 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 151 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 152 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 153 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 154 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 155 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 156 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 157 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 158 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 159 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 160 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 161 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 162 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 163 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 164 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 165 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 166 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 167 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 168 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 169 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 170 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 171 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 172 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 173 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 174 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 175 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 176 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 177 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 178 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 179 JAPAN: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 180 JAPAN: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 181 JAPAN: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 182 JAPAN: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 183 JAPAN: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 184 JAPAN: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 185 JAPAN: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 186 JAPAN: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 187 JAPAN: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 188 JAPAN: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 189 CHINA: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 190 CHINA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 191 CHINA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 192 CHINA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 193 CHINA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 194 CHINA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 195 CHINA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 196 CHINA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 197 CHINA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 198 CHINA: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 199 INDIA: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 200 INDIA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 201 INDIA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 202 INDIA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 203 INDIA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 204 INDIA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 205 INDIA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 206 INDIA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 207 INDIA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 208 INDIA: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 209 SOUTH KOREA: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 210 SOUTH KOREA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 211 SOUTH KOREA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 212 SOUTH KOREA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 213 SOUTH KOREA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 214 SOUTH KOREA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 215 SOUTH KOREA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 216 SOUTH KOREA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 217 SOUTH KOREA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 218 SOUTH KOREA: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 219 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 220 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 221 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 222 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 223 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 224 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 225 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 226 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 227 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 228 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 229 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 230 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 231 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 232 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 233 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 234 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 235 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 236 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 237 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 238 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 239 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 240 MIDDLE EAST: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 241 MIDDLE EAST: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 242 MIDDLE EAST: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 243 MIDDLE EAST: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 244 MIDDLE EAST: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 245 MIDDLE EAST: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 246 MIDDLE EAST: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 247 MIDDLE EAST: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 248 MIDDLE EAST: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 249 MIDDLE EAST: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 250 AFRICA: OSTEOSARCOMA MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 251 AFRICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016-2025 (USD MILLION)
  • TABLE 252 AFRICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 253 AFRICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 254 AFRICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 255 AFRICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 256 AFRICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 257 AFRICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 258 AFRICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016-2025 (USD MILLION)
  • TABLE 259 AFRICA: OSTEOSARCOMA MARKET, BY END USER, 2016-2025 (USD MILLION)
  • TABLE 260 MAJOR MANUFACTURERS IN THE GLOBAL OSTEOSARCOMA MARKET
  • TABLE 261 KEY DEVELOPMENTS BY PLAYERS IN THE MARKET
  • TABLE 262 PFIZER INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 263 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED
  • TABLE 264 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 265 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 266 BAXTER INTERNATIONAL: PRODUCTS/SERVICES OFFERED
  • TABLE 267 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 268 AUROBINDO PHARMA LIMITED: PRODUCTS/SERVICES OFFERED
  • TABLE 269 AUROBINDO PHARMA LIMITED: KEY DEVELOPMENTS
  • TABLE 270 HIKMA PHARMACEUTICALS PLC: PRODUCTS OFFERED
  • TABLE 271 HIKMA PHARMACEUTICALS PLC: KEY DEVELOPMENTS
  • TABLE 272 MYLAN NV: PRODUCTS/SERVICES OFFERED
  • TABLE 273 ADVAXIS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 274 ADVAXIS, INC.: KEY DEVELOPMENTS

List of Figures

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL OSTEOSARCOMA MARKET: STRUCTURE
  • FIGURE 3 RESEARCH PROCESS
  • FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACHES
  • FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL OSTEOSARCOMA MARKET
  • FIGURE 6 DRIVERS: IMPACT ANALYSIS
  • FIGURE 7 RESTRAINTS: IMPACT ANALYSIS
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL OSTEOSARCOMA MARKET
  • FIGURE 9 VALUE CHAIN ANALYSIS OF THE GLOBAL OSTEOSARCOMA MARKET
  • FIGURE 10 PIPELINE ANALYSIS
  • FIGURE 11 GLOBAL OSTEOSARCOMA MARKET, BY TYPE, 2018 (% SHARE)
  • FIGURE 12 GLOBAL OSTEOSARCOMA MARKET, BY TYPE, 2018 TO 2025 (USD MILLION)
  • FIGURE 13 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018 (% SHARE)
  • FIGURE 14 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018 TO 2025 (USD MILLION)
  • FIGURE 15 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2018 (% SHARE)
  • FIGURE 16 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2018 TO 2025 (USD MILLION)
  • FIGURE 17 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2018 AND 2025 (USD MILLION)
  • FIGURE 18 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2018 (% SHARE)
  • FIGURE 19 AMERICAS: OSTEOSARCOMA MARKET SHARE, BY REGION, 2018 (% SHARE)
  • FIGURE 20 EUROPE: OSTEOSARCOMA MARKET SHARE, BY REGION, 2018 (% SHARE)
  • FIGURE 21 ASIA-PACIFIC: OSTEOSARCOMA MARKET SHARE, BY COUNTRY, 2018 (% SHARE)
  • FIGURE 22 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET SHARE, BY REGION, 2018 (% SHARE)
  • FIGURE 23 PFIZER INC. FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 24 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 25 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 26 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS
  • FIGURE 27 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 ELI LILLY AND COMPANY: SWOT ANALYSIS
  • FIGURE 29 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 30 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
  • FIGURE 31 BAXTER INTERNATIONAL: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 32 BAXTER INTERNATIONAL: SWOT ANALYSIS
  • FIGURE 33 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 34 NOVARTIS AG: SWOT ANALYSIS
  • FIGURE 35 AUROBINDO PHARMA LIMITED: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 36 AUROBINDO PHARMA LIMITED: SWOT ANALYSIS
  • FIGURE 37 HIKMA PHARMACEUTICALS PLC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 38 HIKMA PHARMACEUTICALS PLC: SWOT ANALYSIS  
  • FIGURE 39 MYLAN NV: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 40 MYLAN NV: SWOT ANALYSIS
  • FIGURE 41 ADVAXIS, INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 42 ADVAXIS, INC.: SWOT ANALYSIS